MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2017 International Congress

    Inhaling xenon ameliorates L-DOPA-induced dyskinesia in Parkinson disease through normalizing maladaptive corticostriatal plasticity

    E. Bezard, J. Bauffreton, Q. Li, G. Porras, W.K. Ko, E. Pioli, M. Cazalon, S. Morin, G. Farjot, J. Pype, B. Bessiere (Bordeaux, France)

    Objective: To investigate the mechanism(s) of action of xenon inhalation for the treatment of L-DOPA-induced dyskinesia. Background: L-dopa-induced dyskinesia (LID) is one of the most…
  • 2017 International Congress

    Communication Calendar for Interdisciplinary Therapy of Parkinson’s Disease

    F. Adib Saberi, D. Dressler (Hamburg, Germany)

    Objective: To develop a communication calendar (CC) to facilitate information exchange about outpatients treated by various therapists in order to optimize interdisciplinary therapy of Parkinson's…
  • 2017 International Congress

    Botulinum Neurotoxin (BoNT) for treatment of functional (psychogenic) jerky movement disorders: a randomized placebo-controlled clinical trial

    Y. Dreissen, J. Dijk, J. Gelauff, E. Zoons, M. Contarino, R. Zutt, B. Post, D. van Poppelen, A. Munts, J. Speelman, R. de Haan, J. Koelman, M. Tijssen (Amsterdam, Netherlands)

    Objective: To assess the effectiveness of botulinum neurotoxin (BonT) in patients with functional jerky movement disorders Background: At least 2–9% of patients seen in movement…
  • 2017 International Congress

    Antibody-Induced Failure of Botulinum Toxin Therapy: Restart with Incobotulinumtoxina Offers a New Opportunity

    D. Dressler, F. Adib Saberi (Hamburg, Germany)

    Objective: To study whether incobotulinumtoxinA (INCO), a new, low-antigenicity botulinum toxin (BT) drug, increases BT antibody (BTAB) titers in patients with antibody-induced therapy failure (ABTF)…
  • 2017 International Congress

    Intracerebroventricular administration of dopamine: A new therapeutic concept for Parkinson’s disease?

    C. LALOUX, F. GOUEL, C. LACHAUD, K. Timmerman, A. Jonneaux, C. Moreau, R. BORDET, J.-c. DEVEDJIAN, D. DEVOS (LILLE, France)

    Objective: In this study, we aim to demonstrate that continuous i.c.v. infusion of dopamine close to the striatum is a feasible and highly efficient treatment…
  • 2017 International Congress

    Focused ultrasound subthalatomy restores intracortical inhibition in PD

    M. Dileone, R. Martinez-Fernandez, M. Del Alamo, R. Rodriguez, J. Pineda-Pardo, F. Hernandez-Fernandez, J. Obeso, G. Foffani (Mostoles, Spain)

    Objective: To test the effects of focused ultrasound subthalatomy on motor cortex excitability in Parkinson’s disease (PD). Background: Short-interval intracortical inhibition (SICI), a GABAAR-mediated inhibition…
  • 2017 International Congress

    Intranasal delivery of insulin for the restoration of memory signaling in Alzheimer disease

    M. Bhargava, S. Bhargava, V. Bhargava (Kanpur, India)

    Objective: Objective of this study is to develop delivery-system to overcome BBB by employing novel, non-invasive approach via nasal route. The olfactory neural pathway provides…
  • 2017 International Congress

    Multidisciplinary Parkinson rehabilitation delays nursing home admission and is cost-effective.

    E. Steendam-Oldekamp, W. Rutgers, T. van Laar (Groningen, Netherlands)

    Objective: The purpose of this program was to analyze whether activities of daily living (ADL) could be improved, thereby delaying definite nursing home admission and…
  • 2017 International Congress

    AAV-mediated over-expression of VEGF-B in PINK1 gene knockout rats increases striatal dopamine content

    T. Falk, M. Bartlett, D. Muller, B. Silashki, D. Farrell, K. Parent, M. Heien, S. Sherman (Tucson, AZ, USA)

    Objective: To evaluate overexpression of the neuroprotective vascular endothelial growth factor B (VEGF-B) in a genetic Parkinson’s disease (PD) model. Background: We have shown in…
  • 2017 International Congress

    Exercise preferences of people with Parkinson’s disease: preliminary findings of a discrete choice experiment

    C. Canning, C. Canning, S. Paul, J. Bampton, C. Sherrington, K. Howard (Lidcombe, Sydney, Australia)

    Objective: To identify which exercise program attributes most commonly drive willingness of people with Parkinson’s disease (PD) to participate in evidence-based exercise programs. Background: A…
  • « Previous Page
  • 1
  • …
  • 1651
  • 1652
  • 1653
  • 1654
  • 1655
  • …
  • 1942
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley